Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Not Confirmed
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Not Confirmed
Not Confirmed
11-13 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Industry Trade Show
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Industry Trade Show
Not Confirmed
11-13 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/medical-breakthroughs-in-2024-alzheimer-s-schizophrenia-copd-mash-see-pathbreaking-treatments
18 Apr 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/04/18/2865878/0/en/Histogen-Files-for-Voluntary-Chapter-11-Protection-to-Facilitate-Wind-Down-Maximize-Share-Offering.html
14 Dec 2023
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2023/12/14/2796714/0/en/Histogen-Announces-Second-Adjournment-of-Special-Meeting-of-Stockholders.html
05 Dec 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/12/05/2791342/0/en/Histogen-Announces-Adjournment-of-Special-Meeting-of-Stockholders.html
19 Sep 2023
// James Waldron FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/histogen-consigned-history-biotech-winds-down-after-search-strategic-solutions-comes-short
18 Sep 2023
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2023/09/18/2745181/0/en/Histogen-Announces-Board-Approval-of-Complete-Liquidation-and-Dissolution.html
06 Jul 2023
// James Waldron FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/histogen-could-be-history-biotech-halts-all-programs-conserve-remaining-cash
Details:
Under the agreement, the intellectual property covers the use of emricasan, an orally available pan-caspase inhibitor designed to reduce the activities of human caspases, for the treatment of disease in humans resulting from viral or bacterial infections.
Lead Product(s): Emricasan
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Johns Hopkins University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 03, 2023
Lead Product(s) : Emricasan
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Johns Hopkins University
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Histogen Announces Exclusive Intellectual Property License Agreement with Johns Hopkins University
Details : Under the agreement, the intellectual property covers the use of emricasan, an orally available pan-caspase inhibitor designed to reduce the activities of human caspases, for the treatment of disease in humans resulting from viral or bacterial infections...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 03, 2023
Details:
CTS-2090 is a pan-caspase and caspase selective inhibitor that protect the body’s natural process to restore immune function. It has provided protection against inflammation-driven damage to the lining of the GI tract and also protected against loss of body weight.
Lead Product(s): CTS-2090
Therapeutic Area: Infections and Infectious Diseases Brand Name: CTS-2090
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2023
Lead Product(s) : CTS-2090
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Histogen Announces Issuance of US Patent Covering CTS-2090 Methods of Use
Details : CTS-2090 is a pan-caspase and caspase selective inhibitor that protect the body’s natural process to restore immune function. It has provided protection against inflammation-driven damage to the lining of the GI tract and also protected against loss of...
Brand Name : CTS-2090
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 16, 2023
Details:
U.S. FDA has verbally notified the company that it has additional questions about the company’s IND application package for the planned Phase 1/2 clinical trial of HST-003.
Lead Product(s): HST-003
Therapeutic Area: Orthopedics/Orthopedic Surgery Brand Name: HST-003
Study Phase: IND EnablingProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2021
Lead Product(s) : HST-003
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : U.S. FDA has verbally notified the company that it has additional questions about the company’s IND application package for the planned Phase 1/2 clinical trial of HST-003.
Brand Name : HST-003
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
January 19, 2021
Details:
Histogen will retain ownership and oversight over emricasan and responsibility for all regulatory filings and maintaining its existing caspase inhibitor patent portfolio. Amerimmune will lead development efforts of emricasan in a phase 1 study in mild-COVID-19 patients.
Lead Product(s): Emricasan
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Small molecule
Recipient: Amerimmune
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 27, 2020
Lead Product(s) : Emricasan
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Recipient : Amerimmune
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Histogen will retain ownership and oversight over emricasan and responsibility for all regulatory filings and maintaining its existing caspase inhibitor patent portfolio. Amerimmune will lead development efforts of emricasan in a phase 1 study in mild-CO...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 27, 2020
Details:
This blinded, randomized, placebo controlled, single site study has enrolled 36 subjects with male pattern hair loss using a 2:1 randomization of HST-001 to placebo.
Lead Product(s): HST-001
Therapeutic Area: Dermatology Brand Name: HST-001
Study Phase: Phase IProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2020
Lead Product(s) : HST-001
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : This blinded, randomized, placebo controlled, single site study has enrolled 36 subjects with male pattern hair loss using a 2:1 randomization of HST-001 to placebo.
Brand Name : HST-001
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 05, 2020
Details:
Histogen received communications from the Office of Combination Products that HST-002 is a drug-biologic-device combination product. HST-001 1b/2a trial for androgenic alopecia in men on track for top line data results in 4Q20.
Lead Product(s): HST-002
Therapeutic Area: Dermatology Brand Name: HST-002
Study Phase: IND EnablingProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2020
Lead Product(s) : HST-002
Therapeutic Area : Dermatology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Histogen Announces Update for its HST-002 Dermal Filler Program
Details : Histogen received communications from the Office of Combination Products that HST-002 is a drug-biologic-device combination product. HST-001 1b/2a trial for androgenic alopecia in men on track for top line data results in 4Q20.
Brand Name : HST-002
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 29, 2020
Details:
The funding supports Phase 1/2 clinical trial of HST-003 for regeneration of cartilage in the knee led by Histogen. The trial is designed to evaluate HST-003 in combination with a microfracture procedure to treat recent focal cartilage defects in the knee caused by injury.
Lead Product(s): HST-003
Therapeutic Area: Musculoskeletal Brand Name: HST-003
Study Phase: Phase I/ Phase IIProduct Type: Large molecule
Sponsor: U.S. Department of Defense
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Funding September 16, 2020
Lead Product(s) : HST-003
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : U.S. Department of Defense
Deal Size : $2.0 million
Deal Type : Funding
Details : The funding supports Phase 1/2 clinical trial of HST-003 for regeneration of cartilage in the knee led by Histogen. The trial is designed to evaluate HST-003 in combination with a microfracture procedure to treat recent focal cartilage defects in the kne...
Brand Name : HST-003
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 16, 2020
Details:
This blinded, randomized, placebo controlled, single site study is designed to assess the safety and tolerability of HST 001, and indicators of efficacy including non-vellus hair count, total hair count, and hair thickness density as measured by Canfield macrophotography.
Lead Product(s): HST 001
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2020
Lead Product(s) : HST 001
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Histogen Begins Enrollment in Phase 1b/2a Trial of HST 001 to Treat Androgenic Alopecia
Details : This blinded, randomized, placebo controlled, single site study is designed to assess the safety and tolerability of HST 001, and indicators of efficacy including non-vellus hair count, total hair count, and hair thickness density as measured by Canfield...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 01, 2020
Details:
This merger is transformative for Histogen as it looks to advance its novel regenerative medicine pipeline. The merger provides an opportunity for Histogen to become a leader in the aesthetics and orthopedic medicine markets.
Lead Product(s): HST 001
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Large molecule
Recipient: Conatus Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger May 27, 2020
Lead Product(s) : HST 001
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Recipient : Conatus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Merger
Histogen Announces Successful Completion of its Merger with Conatus Pharmaceuticals
Details : This merger is transformative for Histogen as it looks to advance its novel regenerative medicine pipeline. The merger provides an opportunity for Histogen to become a leader in the aesthetics and orthopedic medicine markets.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
May 27, 2020
Details:
Clinical data from the first three cohorts of the ongoing Phase I dose-escalation trial demonstrating safety of MCY-M11 and feasibility of one-day manufacturing will be shared at the ASCO 2020.
Lead Product(s): HST 004
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020
Lead Product(s) : HST 004
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Histogen Publishes Preclinical Data on its HST 004 Spinal Disc Program
Details : Clinical data from the first three cohorts of the ongoing Phase I dose-escalation trial demonstrating safety of MCY-M11 and feasibility of one-day manufacturing will be shared at the ASCO 2020.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 14, 2020
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?